Fluoroethyltyrosine for the Evaluation of Intracranial Neoplasm

a study on Brain Tumor Neoplasms Brain Cancer

Summary

Eligibility
for people ages 4 years and up (full criteria)
Location
at San Francisco, California
Dates
study started
completion around
Principal Investigator
by Javier Villanueva-Meyer, MD
Headshot of Javier Villanueva-Meyer
Javier Villanueva-Meyer

Description

Summary

This is a single center study investigating the use of Fluoroethyltyrosine (FET) in the detection of brain tumors. FET accumulates in malignant cells within intracranial neoplasms and can be used to detect recurrent disease and characterize grade of glial neoplasms.

Details

PRIMARY OBJECTIVES:

  1. To determine if FET Positron Emission Tomography (PET) scan can differentiate between benign treatment-related changes and recurrence in comparison to pathology in population 1 with recurrent metastatic disease and high-grade gliomas.
  2. To determine if FET PET scan can differentiate between low-grade and high-grade gliomas in population 2.

SECONDARY OBJECTIVES:

  1. To determine if FET PET scan can differentiate between benign treatment- related changes and recurrence in comparison to pathology or imaging follow-up in population
  2. To determine if FET PET scan can differentiate between benign treatment- related changes and recurrence in comparison to pathology in population 1 with recurrent low-grade gliomas.

EXPLORATORY OBJECTIVES:

  1. To assess relationships between serial FET PET scan and clinical outcome in population 1 with recurrent metastatic disease and gliomas.

OUTLINE:

Participants will receive a single PET scan lasting for about 40 minutes in an outpatient setting after an injection with FET. Adult participants may undergo up to two repeat FET PET scans. Patient vital signs will be taken immediately before and after the administration of FET, and adverse events will be monitored.

Keywords

Intracranial Neoplasm, Neoplasms, Brain Neoplasms, Fluorethyltyrosine (18-F), Positron Emission Tomography (PET)

Eligibility

You can join if…

Open to people ages 4 years and up

  • Presence or suspicion of intracranial neoplasm in two populations:
    • Population 1: Participants after primary treatment (radiation therapy and/or surgery) with suspicion of recurrence on MRI.
    • Three sub-populations will be considered:
      • Recurrent metastatic lesions.
      • Recurrent high-grade gliomas (Grades 3 and 4).
      • Recurrent low-grade gliomas (Grade 2).
    • Population 2: Participants prior to primary treatment with planned biopsy or surgical resection.
  • Age > 3 years.

Participants in other clinical trials will be eligible for this study including patients undergoing surgery guided by 5-aminolevulinic acid.

You CAN'T join if...

  • Participants with known incompatibility to PET or Computerized tomography (CT)/magnetic resonance imaging (MRI) scans.
  • Participants unlikely to comply with study procedures, restrictions and requirements and judged by the Investigator to be unsuitable for study participation.

Location

  • UCSF accepting new patients
    San Francisco California 94143 United States

Lead Scientist at UCSF

  • Javier Villanueva-Meyer, MD
    Javier Villanueva­-Meyer, MD, is an Associate Professor in the Neuroradiology section in the Department of Radiology and Biomedical Imaging at the University of California, San Francisco. He received his medical degree from Baylor College of Medicine in Houston, Texas, and he completed his one-year internship at Virginia Tech Carilion School of Medicine in Roanoke.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Thomas Hope
ID
NCT06474533
Study Type
Observational
Participants
Expecting 199 study participants
Last Updated
Contact us about this trial